Phaseline

Targets › CREBBP

CREBBP (Histone lysine acetyltransferase CREBBP): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 1; Hematology, Metabolic and endocrine, Oncology; next expected readout Nov 2027.

Acetylates histones, giving a specific tag for transcriptional activation. Mediates acetylation of histone H3 at 'Lys-18' and 'Lys-27' (H3K18ac and H3K27ac, respectively). (UniProt, Q92793)

Open in Phaseline: the race on CREBBP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Kiminori Kimura, MDPri-724
CBP/beta catenin inhibitor
CREBBP, CTNNB1Phase 2Liver CirrhosisNov 2027
Universitas IndonesiaZinc, Chromium, Vitamin C, and Copper Supplementation
Combination mineral and vitamin supplement: zinc enhances insulin signaling and glucose me
SLC30A1, CREBBP, SLC31A1Phase 2PreDiabetes–
Pathos AIPocenbrodib
Selective oral inhibitor of CBP/p300 bromodomain interaction with acetylated lysines on hi
CREBBP, EP300Phase 1mCRPC (Metastatic Castration-resistant Prostate Cancer)Jun 2028

Conditions

Liver Cirrhosis (1) PreDiabetes (1) mCRPC (Metastatic Castration-resistant Prostate Cancer) (1)

Modalities

small molecule (2)

Companies

Kiminori Kimura, MD (1) Universitas Indonesia (1) Pathos AI (1)

Related targets

CTNNB1 (1) SLC30A1 (1) SLC31A1 (1) EP300 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.